Sex-Specific Disparities in Risk Factors for Coronary Heart Disease

Current Atherosclerosis Reports

Volumn 17, Issue 8, 2015, Pages

  Rosen, Stacey E ^a   Henry, Sonia ^a   Bond, Rachel ^a   Pearte, Camille ^b   Mieres, Jennifer H ^a  

^a North Shore LIJ Health System ^*  (United States)

^b Fidelis Care New York ^*  (United States)

Author keywords

Cardiovascular disease in women; Disparities in healthcare; Gender based approach to heart disease

Indexed keywords

ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; RANOLAZINE;

ACUTE STRESS; BLACK PERSON; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEPRESSION; DIABETES MELLITUS; EARLY MENOPAUSE; ELECTROCARDIOGRAM; ETHNIC DIFFERENCE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH DISPARITY; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PHYSICAL INACTIVITY; PREGNANCY COMPLICATION; PROGNOSTIC ASSESSMENT; RACE DIFFERENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SOUTH ASIAN; SYSTEMIC LUPUS ERYTHEMATOSUS; TREADMILL TEST; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; MALE; PREVALENCE; SEXUAL DEVELOPMENT;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; PREVALENCE; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84932619871     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0523-8     Document Type: Review

References (92)

1. Women’s Health Research: progress, pitfalls and promise. Institute of Medicine. Report Brief. September 23, 2010.
2. Mozafferin D, Benjamin EJ, Go AS et al. AHA statistical update: heart disease and stroke statistics- 2015 update. A report from American Heart Association. Circulation 2014 Dec 17: e1-e11.
3. Shaw LJ, Bugiardini R, Bainey MN. Women & ischemic heart disease. J Am Coll Cardiol. 2009;54(17):1561–75.
4. Wenger NK. Women and coronary heart disease: a century after Herrick: understudied, underdiagnosed and undertreated. Circulation. 2012;126:604–11.
5. Mieres JH, Gulati M, Bairey Merz N, American Heart Association Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation. 2014;130:350–79. This updated guideline publication includes an expanded approach to noninvasive testing highlighting new data and new techniques as well as an understanding that ischemic heart disease in women is a heterogeneous condition including both traditional obstructive coronary artery disease as well as those with other etiologies for IHD. The importance of shared decision making is also an important aspect of this publication.
6. Vaccarino V. Angina and cardiac care: are there gender differences, and if so, why? Circulation. 2006;113:467–9.
7. Ford ES, Ajani UA, Craft JB. Explaining the decrease in US deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–98.
8. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. Jama. 1979;241(19):2035–8.
9. Huxley R, Barzi F, Woodword M. Excess risk of fatal coronary heart disease associated with diabetes mellitus in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8.
10. Anand SS, Islam S, Rosengren A, on behalf of the INTERHEART Investigators, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29:932–40.
11. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correa-de-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Iss. 2007;17:120–30.
12. Barett-Connor E. Why women have less heart disease than men and how diabetes modifies women’s usual cardiac protection. Global Heart. 2013;8(2):95–104.
13. Roche MM, Wang PP. Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care. 2013;36(9):2582–90.
14. Bushnell CM, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545–88.
15. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.
16. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90:3863–70.
17. Woods JW. Oral contraceptives and hypertension. Hypertension. 1988;11:II11–5.
18. Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37(3):830–8.
19. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging. 2002;19(3):169–78.
20. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.
21. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women. Circulation. 2004;109:706–13.
22. Broekhuizen LN, Boekholdt SM. Physical activity metabolic syndrome coronary risk: the EPIC-Norfolk prospective population study. Europ J Cardiovasc Prevent Rehabil. 2011;18(2):209–17.
23. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286–8.
24. Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences. Bioinformation. 2012;8(13):613–6.
25. Hillman JK, Johnson LNC, Dokras A. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS. Fertil Steril. 2014;101(2):530–5.
26. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS). Soc J Clin Endocrinol Metab. 2010;95:2038–49.
27. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78:773–6.
28. Hu F, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159(10):1061–6.
29. Mosca L, Benjamin EJ, Berra K. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–62. The first gender-specific guidelines for the prevention of heart disease were published in 1999, and this update includes important new flow diagrams for prevention and a new classification of CVD risk in women and also includes a discussion on disparities, cost-effectiveness, and patient education.
30. Robbins CL, Dietz P, Bombard J, Valderrama A. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol. 2011;204(4):336.e1–9.
31. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population based retrospective cohort study. Lancet. 2005;366:1797–803.
32. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V, Pre-eclampsia and future cardiovascular risk among women. JACC 2014. Vol. 63.
33. Bruce IN, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. Toronto Risk Fact Stud Arthrit Rheumat. 2003;48(11):3159–67.
34. Manzi S, Meildin EN, et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145(5):408–15.
35. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56(10):3412–9.
36. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7(2):227–41.
37. Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev. 2008;4(2):116–22.
38. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 123: e18–e209.
39. Wyman L et al. Depressed mood and cause-specific mortality: a 40-year general community assessment. Ann Epidemiol. 2012;22(9):638–43.
40. Shah AJ, Ghasemzadeh N, Vaccarino V. Sex and age differences in the association of depression with obstructive coronary artery disease and adverse cardiovascular events. J Am Heart Assoc. 2014;3:e000741. originally published June 18, 2014.
41. Lichtman JH, Bigger JT, Froelicher ES, et al. AHA science advisory depression and coronary heart disease: recommendations for screening, referral, and treatment. Circulation. 2008;118:1768–75.
42. Vaccarino V, Shah AJ, Rooks C, Ibeanu I, Nye JA, Pimple P, et al. Sex differences in mental stress-induced myocardial ischemia in young survivors of an acute myocardial infarction. Psychosom Med. 2014;76(3):171–80.
43. Pedrosa RP, Barros IMLm, Costa LOBF, et al. OSA Is common and independently associated with hypertension and increased arterial stiffness in consecutive perimenopausal women, 146#1 CHEST July 2014.
44. Women’s Health Research: progress, pitfalls and promise. Institute of Medicine, Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Report Brief. September 23, 2010. obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62(7):569–57.
45. Campos-Rodriguez F, Martinez-Garcia MA, Almeida-Gonzalez CV, et al. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. Am J Respir Crit Care Med. Volume 189 Number 12 | June 15 2014,
46. Lin CM, Davidson TM, Ancoli-Israel S. Gender differences in obstructive sleep apnea and treatment implications. Sleep Med Rev. 2008;12(6):481–96.
47. Prather AA, Epel ES, Cohen BE, Neylan TC, Whooley MA. Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: findings from the Heart and Soul Study. J Psychiatr Res 2013; 47(9): 10.1016/j.jpsychires.2013.05.004.
48. Miller MA, Ahuja M, Cappuccio FP. Sleep and pregnancy, sleep deprivation, sleep disturbed breathing and sleep disorders in pregnancy. Sleep, 2009: pages 1–14.
49. Mensah G, Mokdad A, et al. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233–41.
50. Go AS et al. AHA heart disease & stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
51. Atherosclerosis Risk in Communities Surveillance (ARIC): 2005–2010 and Cardiovascular Health Study.
52. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation. 2006;113(25):e924–9.
53. Palaniappan L, Wang Y, Fortmann SP. Coronary heart disease mortality for six ethnic groups in California, 1990–2000. Ann Epidemiol. 2004;14(7):499–506.
54. Dave TH, Wasir HS, Prabhakaran D, et al. Profile of coronary artery disease in Indian women: correlation of clinical, non invasive and coronary angiographic findings. Indian Heart J. 1991;43(1):25–9.
55. Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol. 2006;22(3):193–7.
56. Lewey J, Choudry NK. The current state of ethnic and racial disparities in cardiovascular care: lessons from the past and opportunities for the future. Curr Cardiol Rep. 2014;16:530.
57. Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. In: Saunders E, Brest A, editors. Cardiovascular diseases in blacks. Philadelphia: F.A. Davis Company; 1991.
58. Gerhard G. Premenopausal Black women have more risk factors for coronary heart disease than white women. Am J Cardiol. 1998;82:1040–5.
59. Daviglus ML, Talavera GA, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012;308(17):1775–84.
60. Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated lipoprotein(a)—a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. Dis Mon. 2006;52(1):5–50.
61. Mosca L, Hammond G, et al. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association National Survey. Circulation. 2013;127:1254–63.
62. DeVon HA, Zerwic JJ. Symptoms of acute coronary syndromes: are there gender differences? A review of the literature. Heart Lung. 2002;31(4):235–45.
63. Canto JG, Goldberg RJ, Hand MM, Bonow RO, Sopko G, Long T, et al. Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med. 2007;167(22):2405–13.
64. Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813–22.
65. Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J. 2009;157(1):141–8.
66. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. JACC. 2005;45(6):832–7.
67. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001–2010. JACC. 2014;64(4):337–45.
68. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology–National Cardiovascular Data Registry. Circulation. 2008;117:1787–801.
69. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insights from the NHLBI-sponsored women’s Ischemia Syndrome Evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(suppl):S21–9.
70. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295:1404–11.
71. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(suppl):S4–S20.
72. Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005;111:682–96.
73. Cumming GR, Dufresne C, Kich L, Samm J. Exercise electrocardiogram patterns in normal women. Br Heart J. 1973;35:1055–61.
74. Higgins JP, Higgins JA. Electrocardiographic exercise stress testing: an update beyond the ST segment. Int J Cardiol. 2007;116:285–99.
75. Morise AP, Beto R. The specificity of exercise electrocardiography in women grouped by estrogen status. Int J Cardiol. 1997;60:55–65.
76. Murthy VL, Di Carli MF. Noon-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease. Jnucl Cardiol. 2012;1060.
77. O’Donoghue M, Boden WE, Braunwald E. Early invasive vs. conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300:71–80.
78. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–98.
79. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007;50:2111–6.
80. Lansky AJ, Costa RA, Mooney M, et al. for the TAXUS-IV investigators. gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol. 2005;45:1180–5.
81. Abramov D, Tamariz MG, Sever JY, et al. The influence of gender on the outcome of coronary artery bypass surgery. Ann Thorac Surg. 2000;70:800–5. discussion 806.
82. Edwards FH, Carey JS, Grover FL, Bero JW, Hartz RS. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg. 1998;66:125–31.
83. Puskas JD, Edwards FH, Pappas PA, et al. Off-pump techniques benefit men and women and narrow the disparity in mortality after coronary bypass grafting. Ann Thorac Surg. 2007;84:1447–54.
84. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med. 2009;169:843–50.
85. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol. 1999;84:854–6.
86. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974–82.
87. Manfrini O, Pizzi C, Morgagni G, Fontana F, Bugiardini R. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol. 2004;93:1391–3.
88. Danao_glu Z, Kültürsay H, Kayikçio_glu M, Can L, Payzin S. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients. Anadolu Kardiyol Derg. 2003;3:331–7.
89. Cannon 3rd RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411–7.
90. Lerman A, Burnett Jr JC, Higano ST, McKinley LJ, Holmes Jr DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97:2123–8.
91. Schulman SP, Becker LC, Kass DA, Gerstenblith G, et al. L-arginine therapy in acute myocardial infarction the vascular interaction with age in myocardial infarction (VINTAGE MI). JAMA. 2006;295(1):58–64.
92. Mehta PK, Goykhman P, Thomson LE, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. J Am Coll Cardiol Img. 2011;4:514–22.